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The development and validation of a simple and efficient method for the quantification of ferulic acid 
in poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles coated with chitosan (CS) by reverse phase 
high performance liquid chromatography coupled to photodiode array detection was described. For the 
chromatographic analysis, a reverse phase C-18 column was used, mobile phase consisting of acetonitrile 
and 0.5% acetic acid (37:63, v/v), isocratically eluted at a flow rate of 1 mL/min. Drug determination 
was performed at 320 nm. The method was validated in terms of the selectivity, linearity, precision, 
accuracy, robustness, limits of detection and quantification. The method was linear in the range of 10 to 
100 μg/mL (r=0.999) and presented limit of detection and quantification of 102 ng/mL and 310 ng/mL, 
respectively. The method was precise (intra and inter-day) based on relative standard deviation values (less 
than 3.20%). The recovery was between 101.06 and 102.10%. Robustness was demonstrated considering 
change in mobile phase proportion. Specificity assay showed no interference from the components 
of nanoparticles or from the degradation products derived from acidic and oxidative conditions. The 
proposed method was suitable to be applied in determining the encapsulation efficiency of ferulic acid 
in PLGA-CS nanoparticles and can be employed as stability indicating one.
Uniterms: Nanoparticles. Ferulic acid/encapsulation efficiency. Ferulic acid/quantification. Stability. 
High performance liquid chromatography/validation. PLGA-poly(lactide-co-glycolide)/nanoparticles. 
Chitosan.
INTRODUCTION
Trans ferulic acid (FA) [(E) -3- (4-hydroxy-
3-methoxy-phenyl )  p ropy l -2 -eno ic  ac id ]  i s  a 
hydroxycinnamic acid and polyphenolic present in a 
variety of cereals, fruits and vegetables, such as rice, 
coffee, wheat, apple, peanut (Wu et al., 2014), artichoke, 
eggplant and corn meal (Trombino et al., 2013). It 
presents bonded to the cell wall of plants, usually linked 
to proteins and polysaccharides, thus, it is rarely found 
in its free form (Aceituno-Medina et al., 2015). Studies 
indicate the potential use of FA as anti-inflammatory, 
antithrombotic, antitumor, antiviral, immunoprotective, 
antibacterial, protector against ultraviolet rays and 
especially as antioxidant (Kim et al., 2013; Lima, 
Duarte, Esteves, 2013; Yang, Song, 2015). However, FA 
has some limitations that affect its therapeutic efficacy 
when orally administered. It presents broad hepatic 
metabolism (Trombino et al., 2013), reduced half-life, 
low aqueous solubility (Zhou et al., 2015), reduced 
ability to penetrate biological membranes (Trombino et 
al., 2013; Yang, Song, 2015), instability against oxidation 
and low cellular uptake (Kim et al., 2013). An alternative 
to overcome physicochemical, biopharmaceutical and 
pharmacokinetics drawbacks of drugs administered by 
oral route is the use of nanocarrier systems, such as the 
polymeric nanoparticles. 
Polymeric nanoparticles improve drug absorption 
and bioavailability, promote prolonged and/or specific 
drug release, improving the drug uptake by target cells, 
and thus, decreasing its toxicity (De Jong, Borm, 2008). 
The appropriate characterization of nanoparticles is an 
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important step to ensure the therapeutic efficacy. The 
amount of drug-loaded in nanoparticles, drug stability 
and drug delivery profile must be adequately determined, 
and thus, suitable and validated analytical methods are 
necessary (Das Neves et al., 2010). 
FA has been quantified by many analytical methods, 
such as high-performance liquid chromatography 
(HPLC) coupled with photodiode array wavelength 
detector (PDA) or UV-Vis detector (Anselmi et al., 
2006; Craparo et al., 2009; Kareparamban et al., 2013; 
Li et al., 2007; Li et al., 2004; Li, Bi, 2003; Lu et al., 
2005; Nadal et al., 2015; Picone et al., 2009; Qi et 
al., 2007; Wang et al., 2011), liquid chromatography 
tandem mass spectrometry (Guy et al., 2009; Wang et 
al., 2013; Zhang et al., 2009), UV-Vis spectroscopy 
(Lima et al., 2013; Merlin et al., 2012), thin layer 
chromatography (Mabinya, Mafunga, Brand, 2006), 
high-performance thin layer chromatography (Hingse, 
Digole, Annapure, 2014; Srivastava, Singh, Singh 
Rawat, 2012), gas chromatography (Olthof et al., 
2003), chemiluminescence (Shen et al., 2013), capillary 
electrophoresis (Lima, Duarte, Esteves, 2007), micellar 
electrokinetic chromatography (Guo et al., 2003), 
electrochemical analysis (Vilian, Chen, 2014) and 
paper-based platforms (Tee-Ngam et al. ,  2013). 
However, HPLC is considered the most reliable and 
popular methodology for investigating phenolic acids 
(Barberousse et al., 2008). 
Moreover,  most of these studies are about 
quantification of FA coupled with other phenolic 
compounds or other components extracted from plants 
(Andreasen et al., 2000; Guo et al., 2003; Sen et al., 1991; 
Srivastava, Singh, Singh Rawat, 2012; Vichapong et al., 
2010; Waldron et al., 1996), or about the quantification of 
FA in rat plasma (Li, Bi, 2003; Qi et al., 2007; Rondini et 
al., 2004). There are few studies about the analysis of FA 
in products with pharmaceutical potential and among these 
are even rarer those with a documented validation study 
(Nadal et al., 2015). Some studies show the determination 
of FA in lipid nanoparticles (Bondi et al., 2009; Carbone 
et al., 2014; Trombino et al., 2013), metallic (Vilian, 
Chen, 2014), magnetic (Saikia et al., 2013) and in 
poly(lactide-co-glycolide) (PLGA) nanoparticles by UV 
spectrophotometer (Merlin et al., 2012).
Thus, aiming the adequate characterization of 
the FA-loaded nanoparticles and to supply the lack of 
suitable validated methods for quantification of FA in 
pharmaceutical dosages, in this work it was developed 
and validated a simple and fast analytical methodology 
by reverse phase HPLC-PDA to quantify FA in PLGA 
nanoparticles coated with chitosan (CS). 
MATERIAL AND METHODS 
Chemical and reagents
C S  ( m e d i u m  m o l e c u l a r  w e i g h t ,  7 5 - 8 5 % 
deacetylated), FA (99% purity), PLGA (65:35, 40000-
75000 Da), and polyvinyl alcohol (PVA, 31KDa, 88% 
hydrolyzed) were purchased from Sigma Aldrich (St. 
Louis, MO, USA). HPLC grade acetonitrile and ethanol 
were obtained from LiChrosolv-Merck (Darmstadt, HE, 
Germany). Acetic acid was purchased from Vetec Química 
Fina (Duque de Caxias, RJ, Brazil), dichloromethane 
from Fmaia (Belo Horizonte, MG, Brazil), hydrochloric 
acid from Dinâmica (Diadema, SP, Brazil) and hydrogen 
peroxide and sodium hidroxyde were obtained from Biotec 
(Pinhais, PR, Brazil). The water used was purified with a 
Milli-Q Gradient® (Millipore®, Darmstadt, HE, Germany), 
with 18.2 conductivity MΩ/cm.
Chromatographic conditions
For the development and validation of the 
methodology, it was used a HPLC Waters 2695 Alliance 
(Waters®, Milford, MA, USA) combined with a PDA 
Waters 2998 (Waters®, Milford, MA, USA). HPLC 
system was equipped with a column compartment with 
temperature control, on line degasser, quaternary pump, 
auto sampler and auto injector. The analyses were realized 
using a reverse phase C18 chromatograph column 
(Vertical®, Bangkok, Thailand) with 5 μm particle size, 
4.6 mm internal diameter and 250 mm length.
To ensure optimal chromatographic conditions, 
variations in the proportion of components of the mobile 
phase, the sample dilution solvent, the flow rate and in the 
injection volume were performed. The most appropriate 
chromatographic conditions were selected from the 
chromatographic peak characteristics and subsequently 
validated. The mobile phase was composed of acetonitrile 
and 0.5% acetic acid (37:63, v/v), eluted at a flow rate 
of 1.0 mL/min in isocratic mode. The injection volume 
was 10 μL and the analyses were performed at 320 nm at 
25.0±1.0 °C. 
Preparation of standard and sample solutions
A standard stock solution of FA (1 mg/mL) was 
prepared in acetonitrile. After, subsequent dilutions 
in acetonitrile were performed in order to obtain six 
standard solutions (10; 30; 50; 60; 80 and 100 μg/mL). 
FA samples corresponded to supernatant originated after 
ultracentrifugation of nanoparticles containing FA, as 
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described further. Prior to injection, standard and sample 
solutions were filtered through 0.22 μm filter pore size.
System suitability
The system suitability was carried out based on 
the analysis of five replicates of FA standard solution (50 
μg/mL). The system performance was evaluated by the 
following parameters: number of theoretical plates (N), 
tailing factor (T) and retention factor (k).
Method validation
Val ida t ion  was  conduc ted  fo l lowing  the 
guide’s recommendations International Conference 
on Harmonization (ICH) (ICH, 2005) and AOAC 
International Standard (AOAC) (AOAC, 2016). The 
parameters used for this validation were linearity, range, 
accuracy, precision, limit of detection and limit of 
quantification, specificity and robustness. 
Specificity
The specificity was evaluated by comparing the 
chromatograms obtained for the supernatant of blank 
nanoparticles (without FA) and chitosan solution with 
chromatograms of samples containing FA and FA standard 
solution. 
Linearity and range
Linearity of the method was evaluated from the 
construction of three independent calibration curves (peak 
area versus drug concentration) using six FA standard 
solutions (10; 30; 50; 60; 80 and 100 μg/mL). The linearity 
was evaluated by the linear regression and the correlation 
coefficient (r), and can be considered satisfactory if 
(r)≥0.99. The statistical analysis to evaluate the linearity 
and deviation from linearity was performed by analysis of 
variance (ANOVA).
Limit of detection (LOD) and limit of quantification 
(LOQ) 
The LOD and LOQ were obtained based upon 
the slope (S) of the calibration curve and least standard 
deviation obtained from the response (σ), according to Eq. 
1 and Eq. 2 (ICH, 2005) from a specific calibration curve 
constructed by analysis in triplicate of five FA standard 
solutions with concentrations of 0.5; 2; 5; 7 and 10 μg/mL:
  Equation 1
  Equation 2
Precision: repeatability and intermediate precision 
The repeatability of the method was evaluated by 
analysis of FA sample solution (supernatant of FA-loaded 
nanoparticles) in concentrations of 10; 50 and 100 μg/
mL, and for each concentration, five solutions were 
injected on the same day, in a short period of time. To 
the intermediate precision, samples were analyzed in the 
same way, however repeated on three different days. The 
precision was expressed as mean ± standard deviation 
(SD) and relative standard deviation (RSD). 
Accuracy
The accuracy was verified by spiking blank 
nanoparticles with known concentrations of FA solution 
to obtain final concentrations of 10, 50 and 100 μg/mL, 
analyzed in quintuplicate. It was determined the RSD and 
the percentage of recovery (Eq. 3). 
 Equation 3 
Robustness
Robustness was determined by changes in the ratio 
of mobile phase (acetonitrile:0.5% acetic acid - 35:65 
and 39:61 v/v) and in the flow rate (0.95 and 1.05 mL/
min). There were used FA solutions with concentrations 
of 10, 50 and 100 μg/mL. The percentage of recovery 
and the RSD were determined, and to verify the presence 
of significant difference, analysis of variance (ANOVA) 
with Tukey’s multiple comparisons test were performed 
(p<0.05). 
Forced Degradation Studies
For evaluation of drug stability and selectivity with 
respect to degradation products, FA standard solutions (50 
μg/mL) were subjected to forced degradation. Solutions 
were exposed during 24 h to basic hydrolysis (1 mol/L 
NaOH – pH: 13.50), acid hydrolysis (1 mol/L HCl – pH 
0.39), oxidative reaction (3% H2O2), visible light, and 
temperature of -20 °C. 
Method applicability
Nanoparticles containing FA were obtained by the 
single-emulsion solvent evaporation method. Briefly, an 
organic solution was prepared by the dissolution of PLGA 
and FA in ethanol (200 µL) and dichloromethane (1.8 mL). 
The aqueous phase consisted of 10 mL of chitosan solution 
(0.16% w/v) and polyvinyl alcohol (PVA) (1%, w/v), both 
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dissolved in 2% acetic acid (v/v). The organic phase was 
added to the aqueous phase and sonicated for 5 min using 
a probe sonicator (QR1000, Eco-Sonic®, Indaiatuba, SP, 
Brazil) to produce an oil-in-water emulsion. Next, the 
organic solvent was evaporated under vacum for 15 min at 
37 °C by a rotary evaporator (TE 120 - Tecnal®, Piracicaba, 
SP, Brazil). The nanoparticles were recovered and isolated 
of the free drug non-encapusulated by centrifugation 
(19000 rpm, 20 °C, 45 min) (Z36HK Centrifuge, Hermle® 
Wehingen, BH, Germany). The precipitate was freeze-
dried (dispersed in cryoprotectant sucrose 15%, w/v) and 
stored for posterior use. 
Mean diameter and polydispersity index (PDI) 
were analyzed by photon correlation spectroscopy 
using a Dynamic Light Scattering Brookhaven 90 Plus 
(Brookhaven®, Blue Point Road Holtsville, NY, United 
States), at 25 °C, in 90° scattering angle and wavelength 
of 659 nm. The determination of the amount of FA 
encapsulated into nanoparticles was performed indirectly. 
The supernatant obtained after ultracentrifugation of the 
nanoparticle dispersion, which contained the free drug, was 
diluted in acetonitrile (1:100 v/v), filtered on membrane 
pore 0.22 µm and analyzed by HPLC using methodology 
previously validated. The encapsulation efficiency (EE%) 
was obtained from Eq. 4 and expressed as mean EE% and 
SD. Analyses were performed in triplicate.
 Equation 4
where Initial FA represents the amount of FA added to 
the formulation of nanoparticles and free FA represents 
the amount of free drug not incorporated into the 
nanoparticles, quantified by HPLC in the supernatant.
RESULTS AND DISCUSSION
Method development
Brit ish Pharmacopoeia provides a method 
for quantifying FA by HPLC, but its elution is by 
gradient, using phosphoric acid and acetonitrile (British 
Pharmacopoeia Commission, 2011). An isocratic elution 
methodology presents greater simplicity of execution, low 
cost and reduced time. Literature describes solvents, such 
as acetonitrile, methanol, acetic acid, orthophosphoric 
acid, acetate buffer solution and ultrapure water for FA 
determination in plants, plasma and some lipid particles 
(Carbone et al., 2014; Li et al., 2008; Li, et al., 2004; Li, 
Bi, 2003; Lu et al., 2005; Seo et al., 2011; Trombino et 
al., 2013; Wang et al., 2015). Based on literature, initially 
it was tested several proportions of acetonitrile and 0.5% 
glacial acetic acid as mobile phase using a flow rate of 
0.8 mL/min. With low proportions of acetonitrile (less than 
20%), irregular and tailing peaks were obtained, therefore, 
the proportion of the mobile phase was changed to increase 
the amount of acetonitrile. The best peak, in relation to its 
symmetry and width was found using a flow rate of 1.0 
mL/min and a mobile phase composed of acetonitrile: 
0.5% acetic acid (37:63 v/v). In these conditions, FA was 
detected in round to 4.5 min (Figure 1), a time that allows 
a large number of analyzes in a short time and with low 
cost with reagents. 
The system suitability of this method was evaluated 
based on the number of theoretical plates, peak symmetry 
(described by the tailing factor) and retention factor during 
the run of FA standard solution over five repetitions. 
The results presented in Table I and chromatographic 
parameters are in accordance with the criteria established 
by the US FDA (1994).
Method validation
Linearity and range
Linearity indicates the ability of a method to 
demonstrate the results obtained are directly proportional 
to the concentration of analyte existing in the sample 
(ICH, 2005). In the present study, linearity was analyzed 
based on the construction of a calibration curve with six 
different concentrations between 10 and 100 µg/mL and 
by calculating the regression and correlation coefficient 
equation (r) by the method of least squares.
An (r) of 0.999 was obtained, evidencing the 
linearity of the method in this range. Additionally, the 
calculated line equation, y = 54629.2405 (±932.5326) x 
+ 48094.7369 (±24960.6400), was used in subsequent 
assays for quantification of the standard and sample 
solutions. The validity of the test was confirmed by 
ANOVA, which showed the significance of the regression 
and that the deviation from linearity was not significant 
(p <0.0001).
TABLE I - System suitability of the HPLC method (n=5)
Chromatographic 
parameter Result
Acceptance 
criteria
Number of theorical 
plates (N)
3211.07 ± 29.88 N > 2000
Tailing factor (T) 1.09 ± 0.02 T ≤ 2
Retention factor (k) 2.15 ± 0.00 k > 2
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LOD and LOQ 
LOD is the lowest amount of analyte, which can be 
detected in a sample, but not necessarily quantified. LOQ 
demonstrates the lowest amount of analyte determined 
with acceptable accuracy and precision (ICH, 2005). 
For these analyses, a specific calibration curve with 
concentrations below the expected range was constructed 
and analyzed by linear regression. From the SD of the 
intercept with the y-axis and the curve slope, LOD and 
LOQ were calculated.
The ( r )  found was  0 .99917,  thus  meet ing 
recommendations (r of at least 0.99) and confirming the 
linearity of the method (p<0.0001 - ANOVA). From line 
equation, y = 55890.4530 (±796.0461) x - 7244.7629 
(±1730.6330), it was possible to calculate the LOD 
(102.18 ng/mL) and LOQ (309.65 ng/mL). 
Precision: repeatability and intermediate precision 
FA sample solutions in low, medium and high 
concentrations (10, 50, and 100 µg/mL) were prepared 
in quintuplicate and analyzed on the same day (intra-day 
analysis) or on three different days (inter-day analysis) 
to demonstrate the precision at level of repeatability and 
intermediate precision, respectively. According to AOAC 
(2016), to be considered a precise method, the RSD should 
not exceed 5.3% for solutions of 100 µg/mL and 7.3% at 
concentrations of 10 and 50 µg/mL. In this assay, there were 
obtained RSD below the recommended limit, being the 
highest value of 3.15% (Table II). Therefore, the precision 
of the method was confirmed.
Accuracy
Accuracy of the method was demonstrated by the 
percentage of recovery of three different concentrations 
of FA solutions (10, 50 and 100 µg/mL) spiked in blank 
nanoparticles. Results are expressed in Table III, indicating 
the accuracy of the method. According to the AOAC 
(2016), to be considered an accurate method, the recovery 
values should be between 90 and 107% for 100 µg/mL 
solution and between 80 and 110% for 50 and 10 µg/mL.
Specificity
Specificity of the method was evaluated by 
comparing chromatograms of potential formulation 
interferences (supernatant from blank nanoparticles and 
FIGURE 1 - Representative chromatogram of 100 μg/mL FA 
standard solution. Mobile phase: acetonitrile:0.5% acetic acid 
(37:63 v/v), flow rate: 1.0 mL/min, λ: 320 nm.
TABLE II - Precision assay: repeatability and intermediate 
precision (n=5)
FA sample 
solution  
(µg/mL)
Quantified 
concentration 
± SD (µg/mL)
Recovery ± SD 
(%)
RSD (%)
Repeatability
10 9.74 ± 0.31 97.40 ± 3.07 3.15
50 49.30 ± 0.88 98.60 ± 1.76 1.79
100 101.60 ± 1.34 101.609 ± 1.34 1.32
Intermediate precision
Day 1
10 9.74 ± 0.31 97.40 ± 3.07 3.15
50 49.30 ± 0.88 98.60 ± 1.76 1.79
100 101.60 ± 1.34 101.60 ± 1.34 1.32
Day 2
10 10.13 ± 0.12 101.29 ± 1.25 1.23
50 50.53 ± 1.40 101.06 ± 2.79 2.77
100 102.10 ± 1.25 102.10 ± 1.25 1.23
Day 3
10 9.89 ± 0.27 98.88 ± 2.67 2.70
50 48.00 ± 1.05 96.00 ± 2.09 2.18
100 101.59 ± 1.18 101.59 ± 1.18 1.16
FA: Ferulic acid; SD: Standard deviation; RSD: Relative standard 
deviation
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0.5% CS solution) with FA standard solution (Figure 1) 
and FA sample (Figure 2a).
It can be observed in Figure 2, the FA retention time 
in round to 4.5 min (A), however, in the chromatograms 
obtained from the supernatant of blank nanoparticles 
(B) and from the CS solution (C), no peaks were found 
in the same retention time. The results showed there 
was no interference at the retention time of FA from the 
formulation components. In that sense, it is possible to 
confirm the specificity of the purposed method. 
Robustness
Robustness is the ability of the method to resist 
on small and deliberate variations of the analytical 
parameters (ICH, 2005). Table IV shows the results of the 
quantification of FA, represented as percentage of recovery 
and RSD, after changes in the flow rate and in the mobile 
phase. There was no statistical difference in recovery 
obtained by the reference method and when variations 
in the proportion of mobile phase were applied (p>0.05), 
therefore, the method is robust for this change. However, 
the methodology showed to be sensible to changes in the 
flow rate, requiring greater caution and attention for small 
variations in this chromatographic parameter (p<0.05)
Forced degradation studies (stability indicating 
property)
In order to verify the specificity of the method as 
regards the impurities and the degradation products, as 
well as to promote information about the drug stability, 
a forced degradation study was performed. To evaluate 
this parameter, FA standard solutions (50 µg/mL) were 
exposed to basic hydrolysis, acid hydrolysis, oxidation, 
visible light and temperature of -20 °C, and subsequently 
quantified. The chromatograms and percentage of recovery 
are shown in Figure 3 and Table V, respectively. 
The chromatograms of the samples exposed to acid 
hydrolysis, oxidation, visible light and temperature of -20 
°C, did not present alteration in FA retention time, allowing 
its quantification. However, when the FA sample was 
TABLE III - Percent recovery and RSD obtained by the accuracy test (n=5)
Standard solution (µg/mL) Quantified concentration ± SD (µg/mL) Recovery ± SD (%) RSD (%)
10 10.13 ± 0.12 101.29 ± 1.25 1.23
50 50.53 ± 1.40 101.06 ± 2.79 2.77
100 102.10 ± 1.25 102.10 ± 1.25 1.23
SD: Standard deviation; RSD: Relative standard deviation
FIGURE 2 - Representative chromatograms of: A) ferulic acid 
sample solution, B) supernatant from blank PLGA nanoparticles, 
C) 0.5% chitosan solution.
TABLE IV - Robustness results at different levels of flow rate and mobile phase proportion (n=3)
Variation
Recovery ± RSD (%)
10 µg/mL 50 µg/mL 100 µg/mL
Reference 99.32 ± 4.67a 98.04 ± 1.57a 101.02 ± 1.41a
Flow rate 0.95 mL/min 102.40 ± 2.93b 107.25 ± 1.66b 109.12 ± 0.49b
Flow rate 1.05 mL/min 91.27 ± 3.18c 92.59 ± 1.48c 95.57 ± 0.86c
Mobile phase acetonitrile:0.5% acetic acid; 35:65 v/v 100.29 ± 1.89a 102.21 ± 1.05a 104.67 ± 0.99a
Mobile phase acetonitrile:0.5% acetic acid; 39:61 v/v 99.98 ± 1.64a 101.97 ± 1.97a 104.49 ± 0.06a
RSD: relative standard deviation; a, b, c: Means in a column with different superscripts differ significantly (p <0.05) by Tukey’s test
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exposed to alkaline pH, there was a displacement of the 
peak, and the retention time was 4 min. Furthermore, the 
possible degradation product obtained from the alkaline 
hydrolysis changed the FA characteristic peak shape 
(Figure 3b). The chromatogram of the acid degraded 
sample showed one additional peak with very low intensity 
at retention time of 2.2 min (Figure 3c). The chromatogram 
of the FA treated with H2O2 showed an additional peak at 
2.5 min (Figure 3d).
Percentage of recovery (Table V) was adequate for 
exposure to acid medium, visible light and temperature 
of - 20 °C (between 97.49±0.40 and 101.52±0.27), 
indicating stability in these conditions. For the exposure 
to oxidation, the recovery was slightly lower, although 
still in accordance with the AOAC (2016) recommended 
for the concentration of 50 µg/mL (80 to 110%). 
However, after the exposure to basic medium, due to the 
displacement and change of the peak shape by possible 
degradation products, quantification was not possible to 
be performed. 
Method applicability
PLGA nanoparticles containing FA coated with CS 
were properly obtained and presented mean size of 234±15 
nm and polydispersity index of 0.195±0.018, indicating 
homogenous size distribution. EE% was assessed by the 
HPLC method and the results showed about 60±5% of FA 
encapsulated in nanoparticles. Literature shows a similar 
result for FA encapsulated in PLGA nanoparticles (76%) 
(Merlin et al., 2012). 
Due to the relative absence of studies in which 
quantification of FA is carried out in polymeric 
nanoparticles by HPLC, as well as the lack of validation 
and further detailing on the chromatographic methods 
used in other pharmaceuticals products, HPLC-PDA 
method here validated can be considered an alternative 
for the quantitative analysis of FA. The method showed 
to be simple, fast, reliable and it fulfill the requirements 
to be applied in the encapsulation efficiency of FA in 
nanoparticles. Also, the method can be employed as a 
stability indicating one.
CONCLUSIONS
A simple, efficient and reliable method to quantify 
FA in PLGA nanoparticles coated with CS by reversed-
phase HPLC with PDA was developed and adequately 
validated according to ICH and AOAC. The reliability of 
the method has been proven by parameters of linearity, 
range, LOD, LOQ, precision, accuracy, specificity, 
robustness and a study of forced degradation. The 
analytical methodology presented a short retention time, 
allowing rapid quantification of FA with low quantities 
of reagents. Also, the method proved to be suitable for 
evaluating the FA encapsulation efficiency in PLGA-CS 
nanoparticles.
FIGURE 3 - Chromatograms obtained after forced degradation 
test for 24 h. A) Ferulic acid standard solution - Reference (50 
µg/mL) B) After basic hydrolysis (NaOH 1 mol/L) C) After acid 
hydrolysis (HCl 1 mol/L) D) After oxidation (H202 3%) E) After 
exposure to visible light F) After storage at -20 °C.
TABLE V - Results of quantification of FA after forced 
degradation test for 24 h (n=3)
Stress condition
Quantified 
concentration ± SD 
(µg/mL)
Recovery ± SD 
(%)
Reference 50.53 ± 1.40 NA
Basic hydrolysis NQ NQ
Acid hydrolysis 49.26 ± 0.20 97.49 ± 0.40
Oxidation 46.28 ± 1.30 91.59 ± 2.58
Visible light 51.30 ± 0.14 101.52 ± 0.27
-20 °C 50.94 ± 0.82 100.81 ± 1.63
SD: Standard deviation; NA: Not applicable; NQ: Not quantified
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